Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Accumulated Expenses (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Accumulated Expenses for 5 consecutive years, with $15.5 million as the latest value for Q2 2024.

  • For the quarter ending Q2 2024, Accumulated Expenses changed N/A year-over-year to $15.5 million, compared with a TTM value of $15.5 million through Jun 2024, changed N/A, and an annual FY2023 reading of $20.0 million, down 5.16% over the prior year.
  • Accumulated Expenses was $15.5 million for Q2 2024 at Cytek Biosciences, down from $20.0 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $21.1 million in Q4 2022 and bottomed at $9.0 million in Q4 2020.
  • Average Accumulated Expenses over 5 years is $16.2 million, with a median of $15.5 million recorded in 2024.
  • The sharpest move saw Accumulated Expenses soared 68.56% in 2021, then dropped 5.16% in 2023.
  • Year by year, Accumulated Expenses stood at $9.0 million in 2020, then surged by 68.56% to $15.3 million in 2021, then skyrocketed by 38.52% to $21.1 million in 2022, then fell by 5.16% to $20.0 million in 2023, then dropped by 22.69% to $15.5 million in 2024.
  • Business Quant data shows Accumulated Expenses for CTKB at $15.5 million in Q2 2024, $20.0 million in Q4 2023, and $21.1 million in Q4 2022.